IRVINE, CA / ACCESSWIRE / October 4, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Teva Pharmaceutical Industries Limited ("Teva" or the "Company") (NYSE: TEVA). Investors, who purchased or otherwise acquired shares from November 15, 2016 through August 2, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm before the October 23, 2017 lead plaintiff motion deadline.
If you purchased Teva shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Teva issued materially false and/or misleading statements, and/or failed to disclose, that the poor performance of its U.S. generics business resulted in the Company recording a goodwill impairment charge related to the acquisition of Actavis Generics and was a key factor in cutting Teva's dividend by 75%. When this information was released, shares of Teva fell in value materially, which caused investors harm according to the lawsuit.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Joon M. Khang, Esq.
SOURCE: Khang & Khang LLP